Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraStem CellsGraft vs Leukemia EffectBone Marrow TransplantationMyeloablative AgonistsTreatment OutcomeTissue DonorsBusulfanRemission InductionVidarabineRecurrenceGraft vs Tumor EffectGraft SurvivalHistocompatibility TestingLymphocyte TransfusionImmunosuppressive AgentsLeukemia, Myeloid, AcuteMultiple MyelomaLeukemiaCombined Modality TherapyHematopoietic Stem CellsRetrospective StudiesSiblingsCord Blood Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsMinor Histocompatibility AntigensSalvage TherapyDisease-Free SurvivalWhole-Body IrradiationLiver TransplantationLymphocyte DepletionGenetic TherapySurvival AnalysisAntilymphocyte SerumMyelodysplastic SyndromesVirus ActivationSurvival RateNeoplasm, ResidualHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaMelphalanChimerismHepatic Veno-Occlusive DiseaseTime FactorsMesenchymal Stem Cell TransplantationCytomegalovirusCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsT-LymphocytesHematopoietic Stem Cell MobilizationCell TransplantationAcute DiseasePrimary MyelofibrosisAnemia, AplasticKidney TransplantationHLA AntigensEmbryonic Stem CellsFollow-Up StudiesAntigens, CD34Hematologic DiseasesLeukemia, Myeloid, Accelerated PhasePrognosisGanciclovirAntibodies, NeoplasmTransplantation ImmunologyImmunosuppressionRoseolovirus InfectionsCytarabineBenzamidesAdult Stem CellsAntineoplastic AgentsLymphoproliferative DisordersImmunocompromised HostLeukemia, MyeloidFusion Proteins, bcr-ablReceptors, Purinergic P2X5Hodgkin DiseasePyrimidinesGenetic VectorsNuclear FamilyGraft RejectionGranulocyte Colony-Stimulating FactorImmunotherapy, AdoptiveInfectionPiperazinesLymphoma, Non-HodgkinFatal OutcomeCyclosporineHeart TransplantationFlow CytometryCell Differentiation